Dietetic intervention in psoriatic arthritis: the DIETA trial

Table 2 Skin and joint disease activity outcomes before and after a 12-week dietetic intervention

	Baseline	12-week	Difference	p intra group¹
DAS28-ESR
Placebo	3.56 ± 1.3	3.46 ± 1.2	-0.10 ± 1.4	0.3
Diet-Fish	3.31 ± 1.2	3.50 ± 1.4	0.19 ± 1.16	0.3
Diet-Placebo	3.40 ± 1.6	2.90 ± 1.44	-0.49 ± 0.89	0.3
p between groups²	0.52	0.52
DAS28-CRP
Placebo	2.93 ± 1.19	2.72 ± 1.0	-0.21 ± 1.15	0.004
Diet-Fish	2.83 ± 1.55	2.43 ± 1.0	-0.40 ± 1.11	0.004
Diet-Placebo	2.98 ± 1.35	2.33 ± 1.1	-0.66 ± 0.90	0.004
p between groups²	0.84	0.84
PASI
Placebo	2.51 ± 3.8	1.86 ± 1.8	-0.66 ± 3.0	0.3 ^a
Diet-Fish	3.41 ± 6.1	2.79 ± 4.9	-0.62 ± 2.3	0.3 ^a
Diet-Placebo	3.49 ± 6.3	2.67 ± 3.9	-0.82 ± 3.6	0.3 ^a
p between groups²	0.67 ^b	0.67 ^b
BSA
Placebo	3.59 ± 7.04	2.48 ± 3.0	- 0.89 ± 4.7	0.1
Diet-Fish	3.71 ± 5.7	5.04 ± 15.0	0.95 ± 2.4	0.1
Diet-Placebo	5.14 ± 12.9	4.29 ± 9.4	- 0.53 ± 4.4	0.1
p between groups²	0.47	0.47
BASDAI
Placebo	2.94 ± 1.96	2.31 ± 1.84	-0.63 ± 1.5	0.04
Diet-Fish	2.51 ± 1.83	2.70 ± 2.40	0.19 ± 1.67	0.56
Diet-Placebo	3.5 ± 2.23	2.11 ± 1.95	-1.39 ± 1.97	0.001
p between groups²	0.38	0.78
MDA, n (%)
Placebo	6 (18.2%)	9 (27.3%)	+ 9.1%	0.006
Diet-Fish	9 (28.1%)	11 (34.4%)	+ 6.3%	0.006
Diet-Placebo	7 (21.9%)	11 (34.3%)	+ 12.4%	0.006
p between groups²	0.65	0.65

Bold indicates p statistically significant (≤ 0.05)
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, BSA: Body Surface Activity, D: Diet, D + S: Diet plus supplementation, DAS: Disease Activity Score, HAQ: Healthy Activity Questionnaire, MDA: Minimal Disease Activity, P: Placebo, PASI: Psoriasis Activity Severity Index
¹ANOVA with repeated measures or Wilcoxon test (^a)
²ANOVA with repeated measures or Kruskal–Wallis test (^b)

ISSN: 2523-3106